Navigation Links
FDA Approves MiddleBrook's Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
Date:1/24/2008

n, (2) increase Keflex 750 sales, (3) retain marketing approval for its MOXATAG product, (4) successfully reduce costs, (5) reach profitability, (6) prove that the preliminary findings for its product candidates are valid, (7) receive required regulatory approvals, (8) successfully conduct clinical trials in a timely manner, (9) establish its competitive position for its products, (10) develop and commercialize products that are superior to existing or newly developed competitor products, (11) develop products without any defects, (12) have sufficient capital resources to fund its operations, (13) protect its intellectual property rights and patents, (14) implement its sales and marketing strategy, (15) successfully attract and retain collaborative partners, (16) successfully commercialize and gain market acceptance for its Keflex products, (17) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (18) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
2. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
5. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
6. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
7. Surgeons Find That Laparoscopic Banding Procedure Helps Overweight Adolescents Lose Weight and Improve Health
8. New Data Show Unacceptably Low Adult Immunization Rates and That Adults Unaware of Infectious Disease Threat
9. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
10. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...DALE, Pa., Dec. 3 Radiology imagin...-record integration capabilities at the November 2... The Connect.PACS(TM) product, enabling the fir... is the latest release in the company,s newly bran...Photo: http://www.newscom.com/cgi-bin/prnh/20091...
(Date:12/3/2009)...RSHOLM, Denmark and SAN DIEGO, California, Decembe...lly Inhibits miR-122, a microRNA Important for,Hep...Reducing Hepatitis C,Virus in the Bloodstream in C... C Virus , - SPC3649 Demonstrates Efficac...ous Adverse Events in the Treated Animals - Signal...
(Date:12/3/2009)...ec. 3 In response to th...tion technologies in the evolving healthcare deliv...ter for Health Informatics (DCHI) to provide a cam...e an innovative interdisciplinary approach to educ...ians, nurses and healthcare administrators with an...
Breaking Medicine Technology:MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3Par Pharmaceutical Receives Final Approval to Market Generic Ultram 28R 29 ER 6276 1Par Pharmaceutical Receives Final Approval to Market Generic Ultram 28R 29 ER 6276 2Lilly Surpasses United Way 2009 Campaign Goal 6272 1Lilly Surpasses United Way 2009 Campaign Goal 6272 2Lilly Surpasses United Way 2009 Campaign Goal 6272 3Raleigh Day Spa Blue Water Spa Raffles Off 2410 000 in Day Spa Packages for Contributing to Raleigh Food Drive 61407 1Raleigh Day Spa Blue Water Spa Raffles Off 2410 000 in Day Spa Packages for Contributing to Raleigh Food Drive 61407 2
...stic Systems, Inc. (OTC Bulletin Board: SSUR) toda...ent from Inverness Medical Innovations, Inc.,(Amex...ure and Inverness,signed two additional agreements...reby Inverness acquired an option to the exclusive...ertain infectious disease diagnostic,tests develop...
...ERN, Pa., Oct. 17 Cutanea Life Sciences, an,emerg...proving human health,and appearance through the de...diseased and aging skin conditions, today announce...al of Omiganan. The trial compared Omiganan 2.5% ...ulopustular rosacea. Study results demonstrated th...
Other Medicine Technology:StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations 2StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations 3Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 2Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 3Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 4Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 5Cutanea Announces Promising Phase II Results in Rosacea with Omiganan 6
(Date:12/5/2009)... , NEW ORLEANS, Dec. 5 /PRNewswire-USNewswire/ ...erious and often deadly blood cancers. Research pr...erican Society of Hematology introduces potential ...ods for patients suffering from acute promyelocyti... lymphoblastic leukemia, and myelofibrosis that ar...
(Date:12/5/2009)... AVIVA today announced the launch of...ational private medical insurance plan which follo...nt. In addition to offering customers the flexibil...it their needs and budgets, International Solution...mplement those already offered in their country of...
(Date:12/4/2009)...NEW YORK, Dec. 4 Care I...e "Company") today announced that its Board of Dir...of common stock. The dividend is payable on Decem...ecember 14, 2009. ,, About Care Investment ...estate investment and finance company investing in...
(Date:12/4/2009)...WASHINGTON, Dec. 4 The ... Aging (AAHSA) applauds the Senate for ensuring th...CLASS) provisions remain in the final health refor... for providing support to elders, people with disa...Senate to pass a health care reform bill that will...
(Date:12/4/2009)..., ANAHEIM, Calif., Dec. 4 Pamela ...hcare, was selected as a finalist for the "Chief I...scent,s business with the power of cloud computing...ir innovative usage of Salesforce CRM or the Force...uccess to their sales, marketing, partner, service...
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
... Colorado Court of Appeals handed,State Farm Mutua...ng a,trial-court ruling supporting the insurance g...mbursements of medical costs. The ruling, issued ...unilaterally reduced after the insurance,company p...
...rogen Pharmaceuticals,Limited (ASX: PGL; Nasdaq: P...-cancer drug PI-88 has been awarded Fast Track sta.... The fast track designation has been granted,to P... Under the FDA Modernization Act of 1997, the fas...
... Benjamin England,Special Counsel with Jones Walke...ture, Rural Development, Food and Drug Administrat...on Appropriations, on Tuesday, September,25, 2007 ...ategic Plan that relates to the import of food, dr...
...24 While most patients and physicians believe its...xam, theres growing debate about this conventional...ue of the Archives of Internal Medicine raises ser... the number, cost and content of preventive health...
...epressed, distraught were seldom questioned, study...s) -- Pointing to a disconnect between doctors and...ests that large numbers of physicians fail to spot...r a similar disorder. , Only 36 percent of the doc...
... Today, Speaker of the,House Nancy Pelosi (D-CA) a...d Louise Slaughter (D-NY), introduced the Coordina...7. This legislation would establish a,national pub...ards, and increase funding for locally-based pilot...
Other Medicine News:Health News:Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces 2Health News:Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces 3Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 3Health News:Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee 2Health News:New study likely to fuel debate over annual physical exams 2Health News:New study likely to fuel debate over annual physical exams 3Health News:Doctors Often Fail to Spot Suicidal Patients 2Health News:Doctors Often Fail to Spot Suicidal Patients 3Health News:Pelosi, Slaughter and Tubbs Jones Introduce Health Tracking Legislation 2
Buratto Insertion Forceps - Angled
Hydroview Insertion Forceps - Titanium
Hydro Insertion Forceps
Kellan Lens Inserter Forceps
Medicine Products: